p110α and p110β isoforms of PI3K are involved in protection against H2O2 induced oxidative stress in cancer cells

  • Paramjeet Singh
  • Nasima Bano
  • Md Mehedi Hossain
  • Rafia Basit
  • Mohd Jamal DarEmail author
Original Article



Phosphatidylinositol-3 kinases (PI3Ks) are involved in regulating cell growth, proliferation, differentiation, apoptosis and survival. p110α and p110β, two ubiquitously expressed isoforms of PI3K signalling, are involved in growth factor mediated signaling and survival by generating second messengers. Earlier, we have generated GFP-fusion proteins of p110α and p110β and expressed them in normal and cancer cell-lines to investigate their subcellular localization and their role in various activities. Here, we sought to examine the role of p110α and p110β isoforms in protecting MCF-7 breast cancer cells against oxidative stress.

Material methods

We performed cytotoxicity assays, DNA transfection, Plasmid DNA preparation, western blotting, flourscence microscopy and statistical analysis.


To know whether p110α and p110β are involved in protecting MCF-7 breast cancer cells against oxidative stress, we subjected MCF-7 cells to H2O2 treatment and observed a dose dependent decrease in cell viability and a marked increase in the levels of pro-apoptotic markers which include PARP, Bcl-2, Bax and procaspase-9. We then over-expressed recombinant GFP-fusion p110α and p110β proteins in MCF-7 cells and observed a significant decrease in apoptosis and a concomitant increase in pAkt levels.


We report the involvement of p110α and p110β isoforms of Class 1A PI3K signalling in rescue from oxidative stress-induced apoptosis in MCF-7 cells in Akt dependent manner.


PI3K signalling Akt Apoptosis Breast cancer 



This work was supported by a grant from the Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi, under HCP0008. This manuscript represents CSIR-IIIM communication number (IIIM/2255/2018).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Domin J, Waterfield M. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 1997;410:91–5.CrossRefGoogle Scholar
  2. 2.
    Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–19.CrossRefGoogle Scholar
  3. 3.
    Vanhaesebroeck B, Waterfield M. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253:239–54.CrossRefGoogle Scholar
  4. 4.
    Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–44.CrossRefGoogle Scholar
  5. 5.
    Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329–41.CrossRefGoogle Scholar
  6. 6.
    Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol. 1997;7:261–9.CrossRefGoogle Scholar
  7. 7.
    Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101.CrossRefGoogle Scholar
  8. 8.
    Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5-trisphosphate-dependent activation of protein kinase B. Science. 1998;279:710–4.CrossRefGoogle Scholar
  9. 9.
    Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.CrossRefGoogle Scholar
  10. 10.
    Yamaguchi H, Wang H-G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene. 2001;20:7779–86.CrossRefGoogle Scholar
  11. 11.
    Zhang X, Tang N, Hadden TJ, Rishi AK. Akt. FoxO and regulation of apoptosis. Biochim Biophys Acta (BBA) Mol Cell Res. 2011;1813:1978–86.CrossRefGoogle Scholar
  12. 12.
    Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–7.CrossRefGoogle Scholar
  13. 13.
    Singh P, Dar MS, Dar MJ. p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin? FEBS Letters. 2016.Google Scholar
  14. 14.
    Singh P, Dar MS, Singh G, Jamwal G, Sharma PR, Ahmad M, et al. Dynamics of GFP-Fusion p110α and p110β isoforms of PI3K signaling pathway in normal and cancer cells. J Cell Biochem. 2016;117:2864–74.CrossRefGoogle Scholar
  15. 15.
    Kumar A, Redondo-Muñoz J, Perez-García V, Cortes I, Chagoyen M, Carrera AC. Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival. Mol Cell Biol. 2011;31:2122–33.CrossRefGoogle Scholar
  16. 16.
    Shayesteh L, Lu Y, Kuo W-L, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21:99–102.CrossRefGoogle Scholar
  17. 17.
    Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11:2875–8.CrossRefGoogle Scholar
  18. 18.
    Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41:1649–54.CrossRefGoogle Scholar
  19. 19.
    Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678–81.CrossRefGoogle Scholar
  20. 20.
    Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci. 2008;105:2652–7.Google Scholar
  21. 21.
    Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7–24.CrossRefGoogle Scholar
  22. 22.
    Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006;18:77–82.CrossRefGoogle Scholar
  23. 23.
    Carracedo A, Pandolfi P. The PTEN–PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008;27:5527–41.CrossRefGoogle Scholar
  24. 24.
    Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.CrossRefGoogle Scholar
  25. 25.
    Yuan T, Cantley L. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497–510.CrossRefGoogle Scholar
  26. 26.
    Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53:3976–85.PubMedGoogle Scholar
  27. 27.
    Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell. 1995;81:801–9.CrossRefGoogle Scholar
  28. 28.
    Zhou H, Li X-M, Meinkoth J, Pittman RN. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol. 2000;151:483–94.CrossRefGoogle Scholar
  29. 29.
    Matheny RW, Adamo ML. PI3K p110α and p110β have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts. Cell Death Differ. 2010;17:677–88.CrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2018

Authors and Affiliations

  • Paramjeet Singh
    • 1
    • 2
  • Nasima Bano
    • 1
    • 2
  • Md Mehedi Hossain
    • 1
    • 2
  • Rafia Basit
    • 1
    • 2
  • Mohd Jamal Dar
    • 1
    • 2
    Email author
  1. 1.Academy of Scientific and Innovative ResearchNew DelhiIndia
  2. 2.Cancer Pharmacology DivisionCSIR-Indian Institute of Integrative MedicineJammuIndia

Personalised recommendations